GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Name: GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Published: 2019
License: https://creativecommons.org/publicdomain/mark/1.0/

GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

esophageal-squamous-cell-carcinoma gastric-adenocarcinoma gastroesophageal-junction-adenocarcinoma head-and-neck-squamous-cell-carcinoma non-small-cell-lung-cancer pancreatic-adenocarcinoma small-cell-lung-cancer triple-negative-breast-cancer

This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma followed by a Phase 2 Basket Expansion phase in Patients with Specified Metastatic Solid Tumors

Conceptio Open Archive

Analyze & explore related research in Conceptio

Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.

Explore in Search →Connect via MCP / API ↗

This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Analyze & explore related research in Conceptio

Related documents